Related by context. All words. (Click for frequent words.) 69 HPTN 68 iPrEx 68 tenofovir gel 68 oral PrEP 65 Caprisa 64 Microbicide 64 vaginal microbicide 64 Ushercell 63 ONTARGET 63 Salim Abdool Karim 63 LUX Lung 63 PrEP 63 BCIRG 63 VivaGel TM 62 microbicide gel 62 tipranavir 62 cellulose sulphate 62 ToGA 62 HIVNET 61 pre exposure prophylaxis 61 PRO# [002] 61 Intervention Trial GAIT 61 microbicide 61 randomized Phase III 61 iPrEx study 61 Carraguard 61 HeFT 61 AIM HIGH 61 pertuzumab 60 cellulose sulfate 60 Prostate Lung Colorectal 60 phase IIb clinical 60 TASKi2 60 GeoVax vaccine 60 African Tuberculosis Vaccine 60 HuMax EGFr 60 CROI 60 NO# [002] 60 multicentre randomized 59 microbicidal gel 59 BRIM3 59 ENDEAVOR III 59 HCV SPRINT 59 rectal microbicide 59 ExTRACT TIMI 59 raltegravir 59 LEXIVA r 59 Ovarian PLCO Cancer 58 AVADO 58 Ovarian Cancer Screening 58 darunavir 58 VivaGel ™ 58 phase IIb 58 EchoCRT 58 Pre Exposure Prophylaxis 58 TDF FTC 58 viral kinetic 58 MERLIN TIMI 58 teriflunomide 58 darunavir ritonavir 58 Microbicide Development 58 Phase Ib clinical 58 Phase III VISTA 58 tenofovir 58 ORMD 58 ritonavir boosted 58 trastuzumab DM1 T DM1 58 vicriviroc 57 Phase 2a trial 57 SABCS 57 EURIDIS 57 microbicides 57 canakinumab 57 CLL8 57 BufferGel 57 evaluating tivozanib 57 BOLDER II 57 oral ridaforolimus 57 designated HVTN 57 randomized controlled clinical 57 ACCORD Lipid 57 CHAMPION PCI 57 ORAL Sync 57 BARI 2D 57 Perinatal HIV 57 Darunavir 57 oral FTY# 57 Screening Trial 57 CANCIDAS 57 Phase Ib II 57 multicenter placebo controlled 57 protease inhibitor PI 57 ganetespib 57 placebo controlled Phase III 57 ENDEAVOR II 57 subanalysis 57 RE LY ® 57 ANRS 57 ABCSG 57 Glucosamine Chondroitin Arthritis 57 RE LY 57 Elvitegravir 57 STRIDE PD 57 vaginal gel 57 PRECiSE 57 phase IIIb 57 integrase inhibitor 57 Aggressive Reduction 57 huC# DM4 57 Pafuramidine 57 San Antonio Breast Cancer 57 TMC# C# 57 ENDEAVOR IV 57 CCR5 inhibitor 57 neratinib 57 APTIVUS 57 Tenofovir gel 57 confirmatory clinical 56 AIDS Clinical Trials 56 phase IIa clinical 56 riociguat 56 Prostate AdenoCarcinoma Treatment 56 NSABP 56 prospective randomized controlled 56 forodesine 56 ongoing Phase IIIb 56 multicenter clinical 56 SPIRIT IV 56 Digital Mammographic Imaging 56 YONDELIS 56 Kivexa 56 rilpivirine 56 VivaGel 56 Microbicide Trials Network 56 ALLHAT 56 pomalidomide 56 elotuzumab 56 placebo controlled clinical 56 AERAS-#/Crucell Ad# 56 Sym# 56 atazanavir 56 phase IIb study 56 Clinical Antipsychotic Trials 56 AIDS Vaccine 56 ribavirin Copegus 56 Phambili 56 Sorafenib HCC Assessment 56 HCV RESPOND 2 56 randomized Phase IIb 56 BRIM2 56 ELCAP 56 CALGB 56 abacavir lamivudine 56 SWOG 56 PLCO trial 56 Telmisartan 56 eprotirome 56 iniparib 56 TG MV 56 Prostate Cancer Prevention 56 Intervention Effectiveness 56 Edge STudy 56 RGB # 56 evaluating Actimmune 56 Asthma Intervention 56 Tanespimycin 56 bazedoxifene conjugated estrogens 56 RTOG 56 EORTC 56 placebo controlled studies 56 PERSEUS 56 VIR# 56 double blinded randomized 56 PRESEPT 56 GARDASIL ® 56 SUCCEED trial 56 SATVI 55 radezolid 55 Aids Vaccine Initiative 55 Zolinza 55 APPRAISE 55 HVTN 55 Phase IIB 55 registrational Phase 55 CR# vcMMAE 55 ADAGIO study 55 dose escalation clinical 55 PLCO 55 MEND CABG 55 Taxotere ® 55 HPV-#/# 55 assessing T DM1 55 tocilizumab 55 alvespimycin 55 IPTi 55 number NCT# ClinicalTrials.gov 55 NSABP B 55 Phase 2a clinical 55 pivotal bioequivalence 55 DSMB 55 NCI Cancer 55 telmisartan 55 vaginal microbicide gel 55 INCB# [001] 55 enfuvirtide 55 olaparib 55 afatinib 55 multicenter Phase II 55 single dose nevirapine 55 prospective multicentre 55 ISENTRESS 55 tenofovir emtricitabine 55 ASCEND HF 55 Femara letrozole 55 VivaGel R 55 IMPROVE HF 55 EVEREST II 55 tesmilifene 55 ABSORB trial 55 #th Annual Interscience 55 Phase #/#a 55 recurrent ovarian cancer 55 OncoVEX GM CSF 55 EDEMA3 55 ALISTA 55 PRTX 55 fosbretabulin 55 Betaferon ® 55 CUSTOM III 55 phase IIa 55 Spine Patient Outcomes 55 ongoing Phase 1b 55 Stenting Trial CREST 55 NATRECOR R 55 ACCOMPLISH 55 Virulizin ® 55 Multimeric 55 ENESTnd 55 Randomized Phase 55 entecavir 55 ADVANCE PD 55 maraviroc 54 Dasatinib 54 iclaprim 54 Heart Failure Trial 54 microbicide gels 54 multicenter randomized clinical 54 Phase 1b clinical 54 CCR5 mAb 54 AVERROES 54 Phase IIIb 54 lopinavir ritonavir 54 landmark ATHENA 54 Antiretroviral Therapy 54 ENDEAVOR clinical 54 Raptiva ® 54 AZILECT R 54 lasofoxifene 54 active comparator 54 CTRC AACR San Antonio 54 vaginal microbicides 54 Glucosamine chondroitin Arthritis 54 Cholesterol Levels SPARCL 54 Left Ventricular Dysfunction 54 coinfected patients 54 exemestane 54 anastrozole 54 PROVENGE sipuleucel T 54 PFO migraine 54 IIa clinical 54 CERVARIX 54 pramlintide metreleptin combination 54 LymphoStat B 54 discordant couples 54 novel VDA molecule 54 standard chemotherapy regimen 54 Phase Ib study 54 fenretinide 54 ABSORB clinical 54 sustained virologic response 54 pazopanib 54 etravirine 54 Phase 2b study 54 JANUVIA 54 SCD HeFT 54 subgroup analyzes 54 multicenter randomized placebo controlled 54 Aptivus 54 recurrent glioblastoma multiforme 54 CTAP# Capsules 54 CLARITY TIMI 54 decitabine 54 LITHE 54 Oral Interventions 54 Elocalcitol 54 SPIRIT FIRST 54 Diabetes ACCORD 54 SECURE THE FUTURE 54 oral deforolimus 54 nelfinavir 54 Gag polymorphisms 54 NATRECOR ® 54 randomized clinical 54 Rakai Uganda 54 recurrent glioma 54 VADT 54 axitinib 54 BioVant 54 Acute Ischemic Stroke 54 selenium supplementation 54 HYVET 54 RE LY trial 54 apricitabine 54 ZOLINZA 54 FOLOTYN ® 54 transcriptase inhibitor NNRTI 54 atazanavir sulfate 54 PROSTVAC TM 54 oral rivaroxaban 54 inecalcitol 54 IMPROVE IT 54 BY WILLA J. 54 Gilead Viread 54 Phase Ia 54 topical microbicide 54 preclinically 54 pharmacokinetic PK 54 enzastaurin 54 blinded randomized 54 LCP AtorFen 54 Randomized Phase II 54 Evaluation WISE 54 Proellex TM 54 Young Adults CARDIA 54 XmAb# 54 trials RCTs 54 prospective randomized placebo 54 UPLYSO 54 randomized multicenter 54 ECASS 54 odanacatib 54 microbicide trials 54 phase Ib 54 d4T 54 Phase IIIb clinical 53 Randomised 53 ICON7 53 Polycap 53 MADIT II 53 boosted protease inhibitor 53 ALTTO 53 PRE SURGE 53 International Verapamil SR 53 DAPT 53 TRITON TIMI 53 CAMMS# 53 non nucleoside reverse 53 LibiGel Phase III 53 Microbicides 53 multicenter trials 53 INTELENCE 53 saquinavir ritonavir 53 zidovudine lamivudine 53 multicenter Phase III 53 Trial NLST 53 FTC TDF 53 JAIDS 53 ACRIN 53 HAART regimens 53 cinacalcet 53 placebo controlled Phase 53 AVOREN 53 tenofovir Viread 53 Phase 1a clinical 53 farletuzumab 53 cediranib 53 NSABP C 53 virologic 53 AZT zidovudine Retrovir 53 efavirenz emtricitabine 53 Gynecologic Oncology Group 53 WHO UNAIDS 53 Rosuvastatin 53 elvitegravir 53 YERVOY 53 AIR2 Trial 53 Phase 1b trial 53 PCV# 53 Clinical Outcomes Utilizing Revascularization 53 PARTNER Trial 53 Sipuleucel T 53 NRTI 53 MOTIVATE 53 peginterferon alfa 2b 53 multicenter Phase 53 CIMZIA TM certolizumab pegol 53 PEG SN# 53 CARE HF 53 Viread Emtriva 53 nucleotide analogue 53 ritonavir boosted lopinavir 53 ASTEROID 53 quadrivalent HPV vaccine 53 sipuleucel T 53 Vitaxin 53 zidovudine AZT 53 non peptidic protease 53 NOXAFIL 53 MEK Inhibitor 53 ASCO Breast Cancer 53 Velcade bortezomib 53 posaconazole 53 ICAAC 53 indibulin 53 Aggressive Drug Evaluation 53 Adalimumab 53 abacavir Ziagen 53 nucleoside analogue 53 strontium ranelate 53 GISSI 53 GOUT 53 saquinavir 53 non nucleoside HCV 53 Degarelix 53 pitavastatin 53 Health Initiative WHI 53 LPV r 53 Cancer Prevention ATBC 53 ASCO Annual Meeting 53 FEM PrEP 53 interferon gamma 1b 53 NCCTG 53 Prospective Randomized 53 oral Xeloda 53 co trimoxazole 53 invasive candidiasis 53 Lamivudine 53 cetuximab Erbitux 53 Tenofovir 53 treatment naive genotype 53 randomized controlled Phase 53 velafermin 53 TORISEL 53 torezolid phosphate 53 Phase III psoriasis 53 nucleoside analogues 53 randomized controlled clinical trials 53 INVANZ 53 HER2 positive metastatic breast 53 ACTEMRA 53 depsipeptide 53 Dapagliflozin 53 moxifloxacin 53 angiogenesis inhibitor 53 Civacir 53 HGS# 53 Reverset 53 DU #b 53 ABC/3TC 53 TRANSFORMS 53 trabedersen 53 ACTIVE W 53 Phase 1a 53 Intervention Effectiveness CATIE 53 3TC lamivudine Epivir 53 ELACYT 53 nucleoside reverse transcriptase inhibitor 53 Gastrointestinal Cancers Symposium 53 HORIZONS AMI 53 Val HeFT 53 Raltegravir 53 CHAMPION PLATFORM 53 Cardiac Allograft Rejection 53 dapsone 53 mycophenolate mofetil 53 Ranolazine 53 PANVAC VF 53 NCT# ClinicalTrials.gov 53 eltrombopag 52 MADIT 52 CALGB # [001] 52 complete cytogenetic response 52 huN# DM1 52 transcriptase inhibitors NNRTIs 52 degarelix 52 CombAT 52 APTIVUS R 52 bevacizumab Avastin 52 PREVENAR 52 Aptivus ® 52 Tuberculosis Vaccine 52 palonosetron 52 randomized multicenter trial 52 tremelimumab 52 ACTEMRA TM 52 cathepsin K inhibitor 52 pharmacokinetic PK study 52 Maraviroc 52 RG# ITMN 52 double blinded placebo 52 SPARCL 52 AACR NCI EORTC 52 Phase 2b clinical 52 Phase III placebo controlled 52 nab paclitaxel 52 fosamprenavir 52 treatment naïve genotype 52 antiretroviral naïve 52 teriparatide 52 Boceprevir 52 fluvastatin 52 multicenter phase 52 ATACAND 52 Sprycel dasatinib 52 IL# PE#QQR 52 HIV infection 52 Cloretazine ® 52 valent pneumococcal conjugate vaccine 52 pafuramidine 52 Universal Flu Vaccine 52 sitagliptin 52 PREZISTA r 52 NCCTG N# 52 deforolimus 52 Azedra 52 valacyclovir 52 Hepatocellular Carcinoma HCC 52 CIBMTR 52 randomized discontinuation trial 52 lenalidomide Revlimid R 52 male circumcision 52 atrasentan 52 Mipomersen 52 MAGE A3 ASCI 52 gastrointestinal stromal tumors GIST 52 Phase #b/#a clinical 52 investigational integrase inhibitor 52 BioNumerik 52 BARACLUDE R 52 randomized controlled 52 AZT 3TC 52 Bazedoxifene 52 aflibercept 52 multicentre 52 multicenter randomized controlled 52 Jevtana 52 entinostat 52 ROTARIX 52 Gita Ramjee 52 AACR San Antonio 52 Etravirine 52 rALLy clinical trial 52 BR.# 52 Teplizumab 52 abiraterone 52 galiximab 52 ACUITY trial 52 PEG Interferon lambda 52 Trandolapril 52 AA Amyloidosis 52 multicentre randomized controlled 52 human microdosing 52 BZA CE 52 pegylated liposomal doxorubicin 52 RTS S/AS# 52 pegylated interferon alpha 52 Cancer Immunotherapy 52 HORIZONS AMI trial 52 CCR5 antagonist 52 Bowel Project NSABP 52 Nevirapine 52 tolvaptan 52 Safinamide 52 telcagepant 52 ENDEAVOR 52 Chicago Multidisciplinary Symposium 52 antitumor effect 52 Endovascular Valve Edge 52 Abacavir 52 Trial PCPT 52 TAXUS VI 52 PSMA ADC 52 SAR# [004] 52 STICH trial 52 BOTUSA 52 apricitabine ATC 52 T DM1 52 PATH Malaria Vaccine Initiative 52 relapsed MM 52 antiretroviral naive 52 PrEP trials 52 Malaria Vaccine Initiative MVI 52 AZOR 52 subcutaneous PRO 52 atazanavir Reyataz 52 male circumcision reduces 52 Zerit 52 ARV therapy 52 viral kinetics 52 multicenter 52 REYATAZ R 52 adecatumumab 52 multicenter prospective 52 HDL Selective Delipidation 52 prospective multicenter 52 Atrasentan 52 RSD# oral 52 BENICAR HCT 52 ASCO GI 52 ritonavir boosted atazanavir 52 figitumumab 52 Prostate Cancer Clinical Trials 52 Sustiva efavirenz 52 CEQ# 52 D 1mT 52 sunitinib 52 APTIVUS r 52 CYPHER Stent 52 Viread 52 NIH Vaccine 52 CUSTOM II 52 COMFORT II 52 rivaroxaban 52 Mosquirix 52 Quarraisha Abdool Karim 52 BOLDER 52 dutasteride 52 tenofovir DF 52 REVLIMID lenalidomide 52 genotypic resistance 52 prospective observational 52 MADIT CRT 52 REYATAZ ® 52 Antiretrovirals 52 antiretroviral therapy 51 Therapeutics TCT scientific 51 Thorough QT 51 Cohort Study MACS 51 TransVax TM 51 INVIRASE 51 ClinicalTrials.gov 51 Certican 51 PRoFESS 51 RIO Lipids 51 DermaVir 51 VFEND 51 Gemzar ® 51 HF ACTION 51 Peginterferon 51 TYKERB 51 Intelence 51 KRN# 51 Carotid Revascularization Endarterectomy vs. 51 Truvada tablets 51 stavudine 51 ONGLYZA 51 PREVENT IV 51 Hepatitis C Virus 51 sunitinib malate 51 CAELYX 51 dose escalation phase 51 ZFP Therapeutic 51 Pegasys plus Copegus 51 Fludara 51 Herceptin trastuzumab 51 ARB telmisartan 51 COPEGUS 51 Clinical Trials Unit 51 BLP# Liposome Vaccine 51 ROTATEQ 51 Antiretroviral Treatment 51 GeoVax DNA 51 sorafenib tablets 51 topical microbicides 51 prospective randomized multicenter 51 substudy 51 Retrovirology 51 RE MODEL 51 platinum refractory 51 confirmatory Phase 3 51 dosage regimens 51 Amrubicin 51 Diamyd ® 51 virologic failure 51 rosuvastatin 51 nevirapine 51 SPIRIT III 51 Intervention Trial 51 Tipranavir 51 Telaprevir 51 TAXUS ATLAS 51 placebo controlled trials 51 antiretroviral ARV 51 rectal microbicides 51 Sexually Transmitted Infections 51 Torisel 51 SORT OUT III 51 ANCHOR trial 51 triple nucleoside regimen 51 valent adsorbed 51 Xyotax 51 EORTC NCI AACR 51 nitazoxanide 51 HuLuc# 51 Trypanosomiasis 51 antiretroviral 51 Betaferon R 51 inhibitor RG# 51 Dendreon Provenge 51 ixabepilone 51 CYT# potent vascular disrupting 51 phase III ACCLAIM 51 d4T stavudine Zerit 51 Vectibix panitumumab 51 tipranavir ritonavir 51 Vacc 4x 51 mcg dose 51 PROactive study 51 bendamustine 51 MIRCERA 51 viral suppression 51 Epzicom 51 NEUVENGE 51 antiretroviral therapy ART 51 Valopicitabine 51 Christian Loucq director 51 Aflibercept 51 phase IIb trial 51 SYNTAX 51 TMC# [001] 51 TYGACIL 51 Tolamba 51 tenofovir FTC 51 abatacept 51 Viramune 51 Randomized Evaluation 51 NicVAX TM 51 elesclomol 51 Cytolin ® 51 secondary efficacy endpoints 51 NIH Consensus 51 COMBIVIR 51 Multicenter AIDS 51 Phase Ib 51 CLARITY study 51 hyperphenylalaninemia HPA due 51 lorvotuzumab mertansine 51 noninferior 51 Merck Isentress 51 indinavir Crixivan 51 Michigan Comprehensive Cancer 51 Nexavar sorafenib 51 adefovir 51 lipid lowering therapy 51 Dr. Fehlings 51 intravenous bisphosphonates 51 ZACTIMA 51 INTEGRILIN 51 Multicenter 51 Simin Nikbin Meydani 51 rilonacept 51 XGEVA 51 Human Hookworm Vaccine Initiative 51 Theratope 51 Towering scholar 51 Saquinavir 51 Lipid Lowering Treatment 51 OHR/AVR# 51 HBsAg 51 protease inhibitors PIs 51 Phase III randomized controlled 51 darunavir r 51 Phase IIb trial 51 glatiramer acetate 51 Cochrane Systematic Review 51 National Surgical Adjuvant 51 pharmacokinetics PK 51 LY# [002] 51 ribavirin RBV 51 Robert Siliciano 51 plus dexamethasone 51 virologic responses 51 SAAVI 51 paricalcitol 51 docetaxel chemotherapy 51 AIDS Vaccine Initiative 51 Meta analyzes 51 dose escalation trial 51 Copegus ribavirin 51 randomized clinical trials 51 Genitourinary Cancers Symposium 51 Doxil ® 51 glucocorticoid induced osteoporosis 51 AIR CF2 51 RDTs 51 resistant ovarian cancer 51 stavudine d4T 51 INTRON therapy 51 Zarnestra 51 Neoplasia 51 Gefitinib 51 Cethromycin 51 ibandronate 51 Abdool Karim 51 ESMO 51 dapivirine 51 efficacy tolerability 51 Clinical Trial Results 51 HIV integrase inhibitor 51 lapatinib Tykerb 51 peg interferon 51 EmbraceAC 51 zidovudine 51 pharmacokinetic pharmacodynamic 51 Combination REOLYSIN R 51 UNAids 50 EGEN 50 Phase III pivotal 50 Dr. Christian Loucq 50 NNRTI 50 metastatic RCC 50 Mylotarg 50 nonrandomized 50 cotrimoxazole prophylaxis 50 NABTT 50 randomized blinded 50 TMC# r 50 prospective multicenter randomized 50 sorafenib Nexavar 50 XL# SAR# 50 virologic response 50 Abiraterone 50 prelicensure 50 immunotherapeutic vaccine 50 Arch Surg 50 lopinavir ritonavir Kaletra 50 Thiovir 50 HuMax CD# 50 Proxinium TM 50 APRISO 50 prospectively defined 50 pegylated interferons 50 Celebrex celecoxib 50 genital herpes infections 50 Lisa Vetten 50 Didanosine 50 Randomized Clinical Trial 50 pharmacokinetic characteristics 50 trastuzumab Herceptin 50 Renal Cell Carcinoma RCC 50 OLYMPIA registry 50 ONCONASE R 50 protease inhibitor 50 peginterferon 50 TransVax ™ 50 GRNVAC1 50 Dialysis Outcomes 50 GARDASIL 50 Platelet Inhibition 50 nucleoside analog 50 Ixempra 50 endometriosis ovarian cysts 50 Hydroxyurea 50 IMC A# 50 zoledronic acid 50 clinical pharmacology studies 50 recurrent metastatic ovarian cancer 50 aleglitazar 50 metastatic HRPC 50 indinavir 50 RECORD1 50 careHPV 50 NNRTIs 50 zotarolimus eluting stent 50 rALLy trial 50 RoACTEMRA 50 Walid Heneine CDC 50 PERSEUS clinical program 50 Tesmilifene 50 Opportunistic Infections 50 uninfected infants 50 Laquinimod 50 Tocilizumab 50 Advanced Neuroendocrine Tumors 50 TAXUS IV 50 metastatic castration resistant 50 chromium supplementation 50 circumcision reduces 50 REVLIMID ® 50 placebo controlled randomized 50 Cloretazine 50 noninferiority 50 Breaking Clinical Trials 50 ACZ# 50 adalimumab Humira 50 Antiretroviral 50 TACI Ig 50 receiving antiretroviral therapy 50 4SC commented 50 Neck Cancer 50 ATTRACT 50 Sphingomab 50 neoadjuvant treatment 50 #rd Annual CTRC 50 Screening Trial DMIST 50 infantile colic 50 targeting CD# 50 Phase III clinical 50 Acute Myocardial Infarction 50 HCV infected 50 serodiscordant couples 50 bosentan 50 SCIB1 50 Late Breaker 50 Denufosol 50 VIRAMUNE 50 MADIT CRT trial 50 superficial bladder cancer 50 HIV infected 50 dasatinib 50 multicenter study 50 HIV RNA 50 ImmunoVEX HSV2 50 OvaRex MAb 50 solifenacin 50 ZOSTAVAX 50 senicapoc 50 Cancer Vaccines 50 Ocular Hypertension Treatment 50 blinded randomized placebo controlled 50 Protelos 50 lamivudine zidovudine 50 CORD II 50 ELISpot 50 integrase inhibitors 50 Hycamtin 50 relapsed ovarian cancer 50 efalizumab 50 Oral NKTR 50 Prosaptide 50 pegfilgrastim 50 ID NCT# 50 Levofloxacin 50 efavirenz Sustiva 50 reboxetine 50 rindopepimut 50 ECTRIMS 50 Military Malaria Vaccine 50 valsartan 50 eptifibatide 50 basal bolus regimen 50 Valortim R 50 ImQuest 50 CCR5 receptor antagonist 50 Thrombolysis 50 desvenlafaxine succinate 50 NASCOP 50 Alkeran 50 SUPPRELIN R LA 50 paroxetine Paxil 50 Stent Thrombosis 50 MVA nef 50 antiviral efficacy 50 goserelin 50 overactive bladder OAB 50 Phase IIa trial 50 multicenter randomized 50 Acquired Immune Deficiency Syndromes 50 nonoxynol 9 50 PROCHYMAL 50 everolimus eluting stents 50 uncomplicated malaria 50 HPV# 50 pharmacokinetic interactions 50 estrogen progestin 50 icatibant 50 COGENT 50 BioMarck 50 pharmacodynamic effects 50 benazepril 50 Berlin Buch Germany 50 QVA# 50 OncoVEX 50 HAART 50 atorvastatin Lipitor 50 herpes infections 50 chlamydial infection 50 ViiV Healthcare 50 dose escalation Phase 50 metastatic hormone refractory 50 Kaleebu 50 KRAS mutation 50 PXD# 50 ACOSOG Z# 50 HIV prevention 50 Celsentri Selzentry 50 PMTCT 50 vorinostat 50 adalimumab